It's been nearly five years since Moderna (NASDAQ: MRNA) emerged as a biotech industry disruptor, with its COVID-19 vaccine ...

In early 2021, individual investors and institutions hurled money at Moderna stock as if future growth were unlimited.

The pharmaceutical company said, “The allegations that came out in the media are entirely baseless, distorted, and part of a smear campaign" ...

National Institutes of Health officials have urged scientists to remove all references to mRNA vaccine technology from their ...

Scientists say that officials from the National Institutes of Health urged them to remove references to mRNA vaccine technology ...

Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors ...

Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million. It is the first time that Merck has ...

MSD and Moderna’s individualised cancer vaccine mRNA-4157 has shown impressive efficacy in a phase 2b trial in skin cancer melanoma, leaving the partners speculating about a possible regulatory ...

The "Inhalable Biologics Market Size, Share & Trends Analysis Report by Biologics (Peptides & Proteins, Monoclonal Antibodies, RNAi-Based Therapeutics), Application (Diabetes, Cancer), Dosage Form, ...